Home » Topics » BioWorld Science

BioWorld Science
RSS

Rexahn advances phase IIa study of RX-3117 and Abraxane in metastatic pancreatic cancer

May 16, 2018

BioLamina and Novo Nordisk partner to develop novel stem cell-based therapies based on Biolaminins

May 16, 2018

Pivotal study of Dupixent in moderate to severe atopic dermatitis in adolescents meets key endpoints

May 16, 2018

V21-DOS47 immunoconjugate shows promising antitumoral activity in vivo

May 16, 2018

FDA approves Truvada to reduce risk of HIV-1 infection in adolescents

May 16, 2018

Otsuka highlights progress of first quarter 2018

May 16, 2018

Inovio reports new data from phase I study of HIV vaccine Pennvax-GP

May 16, 2018

Aerie submits NDA to FDA for Roclatan

May 16, 2018

CARB-X supports MicrobeDx's development of UTI diagnostic system

May 16, 2018

Dimerix announces plans for phase II trials with DMX-200 in chronic kidney disease

May 16, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...